Soligenix, Inc. (SNGX)
$0.33-5.71%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $5M
- Beta
- 2.00
- P/E (TTM)
- -0.26
- Short % float
- 1.14%
- Days to cover
- 1.0
- SI change
- -17.0%
- 1W
- -8.33%
- 1M
- -8.33%
- vs SPY 1W
- -8.19%
- vs SPY 1M
- -10.84%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 17
- VALUE
- 21
- GROWTH
- 47
- GARP
- 7
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-108.6%
REV YoY-
ROE-181.0%
EPS YoY-
ROA-97.5%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.26
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.80
P/FCF-
EV/EBITDA0.42
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E4.55
ALTMAN Z-
CURR RATIO2.77
ND/EBITDA-
BETA2.00
Company news
FAQ
- What is LOPJLB’s current signal on SNGX?
- LOPJLB’s latest quantitative signal on Soligenix, Inc. (SNGX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is SNGX in?
- Soligenix, Inc. (SNGX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Soligenix, Inc. (SNGX) do?
- Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics division, Soligenix is advancing SGX301 (…